Articles On Cynata Therapeutics (ASX:CYP)

17 Oct 2019 - Biotech company Cynata Therapeutics (ASX:CYP) has decided to withdraw from acquisition discussions with Sumitomo Dainippon Pharma Co.

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Strong gains among selected life science shares is fuelling optimism the sector may have further to run. Life sciences stocks are involved in things like biotech, genetics, pharmaceuticals and medical devices. In a low growth earnings envir...

Australian regenerative medicine company Cynata Therapeutics (ASX:CYP) has announced it has received the US$3 million relating to Fujifilm exercising its license option in graft-versus-host disease.

Do you know that on this day in 1970 the great American rock guitarist, singer, and songwriter Jimi Hendrix passed away. James Marshall 'Jimi' Hendrix’s mainstream career lasted only four years, but he is widely regarded as one of the most...

Australian regenerative medicine company Cynata Therapeutics (ASX:CYP) has announced Fujifilm has exercised its license option in graft-versus-host disease.

On Stockhead today, the gold M&A just keeps rolling with Azumah the latest takeover target, SRJ reveals why it thinks Oz is a good place for it to list and the industry that billionaire investor Stephen Schwarzman sees as having ‘Amazon...

Cynata Therapeutics Ltd [ASX:CYP] reported a massive win late last night. Their Japanese benefactor, Fujifilm, is going to license their CYP-001 treatment. The post Fujifilm Takes the Plunge on Cynata appeared first on Money Morning Austra...

Following a successful phase one clinical trial, FUJIFILM Corporation (Fujifilm) has exercised its option to commercialise Cynata Therapeutics’ (ASX: CYP) mesenchymal stem cell product which can treat and prevent graft-versus-host disease i...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Shares in biotech Orthocell (ASX:OCC) are on the move again today after the company reported further positive results for its CelGro technology. Patients who completed the company’s CelGro tendon regeneration trial reported they had regaine...

04 Sep 2019 - Clinical-stage biotechnology company Cynata Therapeutics (ASX:CYP) is excited to have a scientific paper published on the efficacy of Cymerus MSCs in a preclinical mo…

Pharmaxis, one of last year’s biggest small cap reporting season winners, has tumbled 412 per cent into the red as its fortunes fluctuate on the anti-inflammatory drug it sold to German pharma giant Boehringer Ingelheim four years ago. Afte...

The Credible Labs Inc (ASX: CRD) share price looks set to storm higher this morning after the San Francisco-based consumer finance marketplace operator announced that it has entered into a definitive merger agreement with a subsidiary of F...

Japanese company Sumitomo Dainippon Pharma has moved to acquire Australian cell therapy company Cynata Therapeutics (ASX:CYP).

Healthcare being a large industry in Australia is a significant contributor to the country’s economy. The below-mentioned ASX listed healthcare stocks have been performing well over the past few months, plus have made strong operational pro...

Sponsored Content Sumitomo Dainippon Pharma, a $10 billion Japanese pharma company listed on the Tokyo Stock Exchange, has lobbed a $204 million takeover bid for Cynata Therapeutics (ASX:CYP). At a Glance Cynata has revealed it received a t...

The S&P/ASX 200 index has charged higher on Friday thanks largely to strong gains in the banking sector. In afternoon trade the benchmark index is up 0.7% to 6,697.5 points. Four shares that have climbed more than most today are listed...

Melbourne's Cynata Therapeutics says it doesn't believe a $202 million takeover offer it disclosed on Friday explains why its shares rose recently.

ASX shares at the smaller end of the market are outperforming along with the Australian dollar as the global investors up their bets that the US Federal Reserve will make its biggest ever interest rate cut in over 10 years. The S&P/ASX...

Stem cell manufacturer Cynata Therapeutics (ASX: CYP) has announced this morning it has received an acquisition proposal. Japanese pharmaceutical company Sumitomo Dainippon Pharma has proposed to acquire the company for $2 per share (which...

The Cynata Therapeutics Ltd (ASX: CYP) share price has been one of the best performers on the local market in morning trade. At the time of writing the clinical-stage stem cell and regenerative medicine company’s shares are up 15.5% to $1....

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Special Report: Stem cells still have somewhat of a bad rep, as news headlines either repeat the embryo origin story or recount shills promising them as a cure-all for everything from ADHD to Alzheimer’s. But beneath those headlines is a fl...